CN1159300C - 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途 - Google Patents

1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途 Download PDF

Info

Publication number
CN1159300C
CN1159300C CNB988056755A CN98805675A CN1159300C CN 1159300 C CN1159300 C CN 1159300C CN B988056755 A CNB988056755 A CN B988056755A CN 98805675 A CN98805675 A CN 98805675A CN 1159300 C CN1159300 C CN 1159300C
Authority
CN
China
Prior art keywords
weak
difluorobenzyl
triazole
carboxamide
moderate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB988056755A
Other languages
English (en)
Chinese (zh)
Other versions
CN1259127A (zh
Inventor
R
R·波特曼
÷
U·C·霍夫梅尔
A·布克哈德
W·谢尔
ά
M·司泽拉吉维茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4209650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1159300(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1259127A publication Critical patent/CN1259127A/zh
Application granted granted Critical
Publication of CN1159300C publication Critical patent/CN1159300C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB988056755A 1997-06-10 1998-06-08 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途 Expired - Lifetime CN1159300C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH140497 1997-06-10
CH1404/1997 1997-06-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100473675A Division CN1298708C (zh) 1997-06-10 1998-06-08 1－（2，6－二氟苄基）－1h－1，2，3－三唑－4－甲酰胺的结晶改良体及其用途

Publications (2)

Publication Number Publication Date
CN1259127A CN1259127A (zh) 2000-07-05
CN1159300C true CN1159300C (zh) 2004-07-28

Family

ID=4209650

Family Applications (3)

Application Number Title Priority Date Filing Date
CNB988056755A Expired - Lifetime CN1159300C (zh) 1997-06-10 1998-06-08 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途
CN988000113A Expired - Lifetime CN1132820C (zh) 1997-06-10 1998-06-08 药物的结晶改良体
CNB2004100473675A Expired - Lifetime CN1298708C (zh) 1997-06-10 1998-06-08 1－（2，6－二氟苄基）－1h－1，2，3－三唑－4－甲酰胺的结晶改良体及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN988000113A Expired - Lifetime CN1132820C (zh) 1997-06-10 1998-06-08 药物的结晶改良体
CNB2004100473675A Expired - Lifetime CN1298708C (zh) 1997-06-10 1998-06-08 1－（2，6－二氟苄基）－1h－1，2，3－三唑－4－甲酰胺的结晶改良体及其用途

Country Status (36)

Country Link
US (6) US6740669B1 (https=)
EP (2) EP0994864B1 (https=)
JP (2) JP3672575B2 (https=)
KR (2) KR100425656B1 (https=)
CN (3) CN1159300C (https=)
AR (4) AR012946A1 (https=)
AT (2) ATE232852T1 (https=)
AU (2) AU725528B2 (https=)
BR (2) BR9804947A (https=)
CA (3) CA2614926C (https=)
CO (2) CO4940448A1 (https=)
CY (1) CY2007014I2 (https=)
CZ (2) CZ292481B6 (https=)
DE (3) DE69813560T2 (https=)
DK (2) DK0994864T3 (https=)
ES (2) ES2192779T3 (https=)
FR (1) FR07C0037I2 (https=)
HU (2) HU225153B1 (https=)
ID (2) ID27660A (https=)
IL (2) IL125733A (https=)
LU (1) LU91345I2 (https=)
MY (2) MY120156A (https=)
NL (1) NL300284I2 (https=)
NO (2) NO329315B1 (https=)
NZ (2) NZ331370A (https=)
PE (2) PE79799A1 (https=)
PL (2) PL192114B1 (https=)
PT (1) PT994864E (https=)
RU (2) RU2198167C2 (https=)
SI (2) SI0994864T1 (https=)
SK (2) SK283734B6 (https=)
TR (2) TR199801631T1 (https=)
TW (2) TW403740B (https=)
UY (1) UY25844A1 (https=)
WO (2) WO1998056772A1 (https=)
ZA (2) ZA984967B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
MXPA04011865A (es) * 2002-05-31 2005-03-31 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v.
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20090069390A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched rufinamide
JP2012505191A (ja) 2008-10-13 2012-03-01 シプラ・リミテッド ルフィナマイドの製造方法
CN101768124B (zh) * 2008-12-30 2012-01-04 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
IT1395736B1 (it) 2009-08-04 2012-10-19 Dipharma Francis Srl Forme cristalline di rufinamide
MX2012002730A (es) * 2009-09-04 2012-07-20 Tactical Therapeutics Inc Nuevas composiciones y procesos para preparar formulaciones de 1,2,3-triazoles 5-amino o amino sustituidos y triazol orotato.
EP2465853A1 (en) * 2010-12-14 2012-06-20 Laboratorios Lesvi, S.L. Polymorph of rufinamide and process for obtaining it
EP2563766B1 (en) * 2010-04-30 2014-06-25 Laboratorios Lesvi, S.L. Improved process for preparing rufinamide intermediate
ITMI20110718A1 (it) * 2011-04-29 2012-10-30 Dipharma Francis Srl Procedimento per la purificazione di rufinamide
US10206874B2 (en) 2012-07-20 2019-02-19 Hetero Research Foundation Rufinamide solid dispersion
WO2021099481A1 (en) 2019-11-20 2021-05-27 Medichem, S.A. Solid composition containing rufinamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992378A (en) 1973-12-26 1976-11-16 Eli Lilly And Company Fluoralkyl quinoxadinediones
US4156734A (en) * 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
GB1511195A (en) 1976-10-18 1978-05-17 Ici America Inc Triazole derivatives
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4346097A (en) * 1980-09-30 1982-08-24 Warner-Lambert Company Method for treating convulsions with pyrazole-4-carboxamide derivatives
US4789680A (en) * 1982-12-23 1988-12-06 Ciba-Geigy Corporation Aralkyltriazole compounds
FI834666A7 (fi) 1982-12-23 1984-06-24 Ciba Geigy Ag Foerfarande foer framstaellning av nya aralkyltriazolfoereningar.
US4511572A (en) * 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
FI93544C (fi) * 1985-04-18 1995-04-25 Ciba Geigy Ag Menetelmä fluorattujen, antikonvulsiivisesti vaikuttavien 1-bentsyyli-1H-1,2,3-triatsoliyhdisteiden valmistamiseksi
CA2002864C (en) 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
JPH02214504A (ja) 1989-02-15 1990-08-27 Nissan Chem Ind Ltd 光学活性キノキサリン化合物の晶析法
EP0484437A4 (en) 1989-07-27 1994-06-01 Searle & Co Renal-selective prodrugs for the treatment of hypertension
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
ATE194985T1 (de) 1990-11-06 2000-08-15 Yamanouchi Pharma Co Ltd Kondensiertes pyrazinderivat
JP2753911B2 (ja) 1991-12-06 1998-05-20 キッセイ薬品工業株式会社 Ｎ−ｔｅｒｔ−ブチル−１−メチル−３，３−ジフェニルプロピルアミン塩酸塩の結晶多形およびその製造方法
DE4217952A1 (de) 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5631373A (en) 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
GB9418443D0 (en) 1994-09-13 1994-11-02 Pfizer Ltd Therapeutic agents
GB9419318D0 (en) 1994-09-24 1994-11-09 Pfizer Ltd Therapeutic agents
US6096779A (en) 1995-02-22 2000-08-01 Hoechst Pharmaceuticals & Chemicals K.K. Amorphous piretanide, piretanide polymorphs, process for their preparation and their use
DK0918758T3 (da) * 1996-07-11 2002-08-19 Novartis Ag Fremgangsmåde til fremstilling af 1-substituerede 4-cyan-1,2,3-triazoler
TW403740B (en) * 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide

Also Published As

Publication number Publication date
NZ331371A (en) 2000-08-25
MY120156A (en) 2005-09-30
CN1132820C (zh) 2003-12-31
US20010037029A1 (en) 2001-11-01
ES2197485T3 (es) 2004-01-01
RU2194041C2 (ru) 2002-12-10
US8076362B2 (en) 2011-12-13
CA2256013A1 (en) 1998-12-17
KR100409168B1 (ko) 2004-01-31
HUP0000798A2 (hu) 2000-10-30
NO983666L (no) 1998-12-17
KR19990087836A (ko) 1999-12-27
PL191943B1 (pl) 2006-07-31
UY25844A1 (es) 2001-08-27
US6455556B2 (en) 2002-09-24
ATE232852T1 (de) 2003-03-15
US20100310655A1 (en) 2010-12-09
TW526195B (en) 2003-04-01
PE79799A1 (es) 1999-09-03
CZ253498A3 (cs) 1999-04-14
ZA984966B (en) 1999-01-11
CA2256013C (en) 2007-10-16
WO1998056772A1 (en) 1998-12-17
NL300284I1 (nl) 2007-10-01
NO983667D0 (no) 1998-08-11
CN1259127A (zh) 2000-07-05
RU2198167C2 (ru) 2003-02-10
SK109498A3 (en) 1998-12-02
PL330764A1 (en) 1999-05-24
CO4940452A1 (es) 2000-07-24
EP0994863B1 (en) 2003-02-19
ID21014A (id) 1999-04-08
BR9804947A (pt) 1999-08-24
PL330798A1 (en) 1999-06-07
DE69811500D1 (de) 2003-03-27
CA2614926A1 (en) 1998-12-17
CN1217716A (zh) 1999-05-26
IL125733A (en) 2002-12-01
SK283685B6 (sk) 2003-12-02
FR07C0037I2 (https=) 2008-05-16
HK1028241A1 (en) 2001-02-09
FR07C0037I1 (https=) 2007-08-17
US7750028B2 (en) 2010-07-06
DK0994864T3 (da) 2003-07-21
NO329314B1 (no) 2010-09-27
AR061005A2 (es) 2008-07-30
HUP0000798A3 (en) 2000-10-30
ES2192779T3 (es) 2003-10-16
EP0994864B1 (en) 2003-04-16
AR012946A1 (es) 2000-11-22
ZA984967B (en) 1999-01-11
EP0994864A1 (en) 2000-04-26
AU725517B2 (en) 2000-10-12
CZ292481B6 (cs) 2003-09-17
CO4940448A1 (es) 2000-07-24
AU8437198A (en) 1998-12-30
CY2007014I1 (el) 2009-11-04
US6740669B1 (en) 2004-05-25
IL125732A0 (en) 1999-04-11
CA2614926C (en) 2010-02-09
HK1028031A1 (en) 2001-02-02
US20030125568A1 (en) 2003-07-03
EP0994863A1 (en) 2000-04-26
NO983667L (no) 1998-12-17
LU91345I9 (https=) 2018-12-31
PT994864E (pt) 2003-07-31
DK0994863T3 (da) 2003-05-26
AU725528B2 (en) 2000-10-12
NZ331370A (en) 2000-08-25
US20040167186A1 (en) 2004-08-26
CY2007014I2 (el) 2009-11-04
HU226107B1 (en) 2008-04-28
WO1998056773A1 (en) 1998-12-17
IL125732A (en) 2002-12-01
CZ292260B6 (cs) 2003-08-13
ID27660A (id) 2001-04-19
LU91345I2 (fr) 2007-09-04
DE122007000051I2 (de) 2009-02-19
NL300284I2 (nl) 2007-11-01
US20060116520A1 (en) 2006-06-01
HK1028242A1 (en) 2001-02-09
SI0994864T1 (en) 2003-10-31
CN1298708C (zh) 2007-02-07
AU8437298A (en) 1998-12-30
DE69813560D1 (de) 2003-05-22
KR19990087835A (ko) 1999-12-27
TW403740B (en) 2000-09-01
HUP0002113A3 (en) 2002-09-30
NO329315B1 (no) 2010-09-27
AR061004A2 (es) 2008-07-30
TR199801630T1 (xx) 1999-06-21
JP2000516259A (ja) 2000-12-05
DE69811500T2 (de) 2004-04-01
CZ253398A3 (cs) 1999-04-14
TR199801631T1 (xx) 1999-06-21
JP2000516258A (ja) 2000-12-05
CN1572789A (zh) 2005-02-02
PE80999A1 (es) 1999-09-06
AR012945A1 (es) 2000-11-22
BR9804946A (pt) 1999-08-24
SK109398A3 (en) 1998-12-02
PL192114B1 (pl) 2006-08-31
SK283734B6 (sk) 2003-12-02
CA2256015C (en) 2008-06-03
ATE237599T1 (de) 2003-05-15
IL125733A0 (en) 1999-04-11
NO983666D0 (no) 1998-08-11
HUP0002113A2 (hu) 2001-02-28
CA2256015A1 (en) 1998-12-17
DE69813560T2 (de) 2004-02-05
DE122007000051I1 (de) 2007-11-08
SI0994863T1 (en) 2003-08-31
HU225153B1 (en) 2006-07-28
JP3672575B2 (ja) 2005-07-20
JP3672574B2 (ja) 2005-07-20
MY125854A (en) 2006-08-30
KR100425656B1 (ko) 2004-05-17

Similar Documents

Publication Publication Date Title
CN1159300C (zh) 1-(2,6-二氟苄基)-1h-1,2,3-三唑-4-甲酰胺的结晶改良体及其用作抗癫痫药的用途
CN1061656C (zh) 制备具有两种晶形的四唑衍生物的方法及所述衍生物的新晶形
CN1125067C (zh) 结晶抗真菌多晶型物
CN1068878C (zh) 唑酮类氨磺酰衍生物抗螺杆菌剂
CN1152311A (zh) 抗螺杆菌的唑酮类酰基衍生物
EP1212325A2 (en) A novel crystalline form of disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid salt and processes therefor
CN1181064C (zh) 结晶形式的n－(4－三氟甲基苯基)－5－甲基异噁唑－4－甲酰胺的制备方法
CN1065460A (zh) 衍生于苯并咪唑的新的非镇静抗组胺剂
CN1656097A (zh) 黄嘌呤磷酸二酯酶v抑制剂多晶型物
WO2011135105A1 (en) Improved process for preparing rufinamide intermediate
JP2009235088A (ja) ５−ヒドロキシ−１−メチルヒダントイン結晶の製造方法
EP2162453A1 (en) Crystalline form b of olmesartan medoxomil
CN1214029C (zh) 4－氨基－6,7－二甲氧基－2－(5－甲磺酰氨基－1,2,3,4－四氢异喹啉－2－基)－5－(2－吡啶基)喹唑啉甲磺酸盐及多晶形物
HK1040078A1 (en) Crystal forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide
HK1028031B (en) Crystal modification of 1-(2,6-difluorobenzyl)-ih-1,2,3-triazole-4-carboxamide and its use as antiepileptic
HK1020051A (en) Crystal modification of a pharmaceutical agent
HK1028242B (en) Crystal modification of 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide and its use as antiepileptic
CN1694884A (zh) Ⅰ晶型、ⅱ晶型、ⅲ晶型泛昔洛韦及其制备方法
JPH029864A (ja) 新規な２−アゾリル−１−シクロプロピルエタノール誘導体およびその塩

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1028031

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20040728